EVGNNasdaqAgricultural ChemicalsFiscal year ends December 31
Evogene Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$0.37−0.02 (-4.71%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 0.3
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
-6.3%−51.1 pts over 5 years
Operating margin
-364.2%+2021.7 pts over 5 years
Net margin
-220.2%+2027.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -30.9% | +32.0% | +29.9% | -10.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -20.5% | -48.6% | 1107.0% | |
| Return on assets | – | -32.6% | -28.3% | |
| Current ratio | 17.13 | 5.36 | 4.54 | |
| Interest coverage | -23.7× | -8.4× | -7.3× | |
| Inventory turnover | – | – | 4.0× | |
| Capex to revenue | 12.4% | 65.6% | 3.5% | |
| Diluted shares | 3M | 3M | 8M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Evogene generated $103.17M from operations and spent $3.36M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$103.17M
Used
$3.36M
Capital expenditure$3.36M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-220.2%
×Asset turnover0.13×
×Equity multiplier-39.08×
=Return on equity, FY20251107.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -220.2% | 0.13× | -39.08× | 1107.0% |
| FY2024 | -295.6% | 0.12× | 8.58× | -311.0% |
| FY2023 | -800.8% | 0.06× | 2.68× | -119.4% |
| FY2022 | -1590.3% | 0.03× | 1.62× | -65.3% |
| FY2021 | -2988.5% | 0.01× | 1.49× | -55.8% |
| FY2020 | -2247.5% | 0.01× | 1.49× | -48.6% |
| FY2019 | -2405.3% | 0.01× | 1.30× | -36.2% |
| FY2018 | -1188.2% | 0.03× | 1.14× | -34.8% |
| FY2017 | -616.3% | 0.04× | 1.11× | -26.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$8.49M
- Cash generatingOperating cash flow above zero-$13.50M
- Return on assets improvedROA up on the prior year-32.3% → -21.3%
- Earnings backed by cashOperating cash flow above net income-$13.50M vs -$8.49M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.15 → 4.54
- No dilutionShare count did not rise6M → 8M
- Gross margin improvedGross margin up on the prior year57.32% → -6.25%
- More efficientAsset turnover rose0.11 → 0.10